The rise of passive investing is making markets “less efficient and more fragile”, says Tom Stevenson in The Telegraph. Somewhere between a third and half of equity assets under management are now passive, meaning they are held by funds seeking to track market indexes without trying to beat them. Passive investing offers lower fund manager fees than the active variety.
The problem? Too much passive investing makes for less discerning capital allocation, with money blindly pouring into markets according to “fund flows” and “weightings”. Share prices are thus prone to becoming disconnected from reality – although more inefficient markets do at least open the way for active stock pickers to spot mispricing opportunities and scoop up bargains.
Are ETFs following?
A new generation of actively managed exchange-traded funds (ETFs) is trying to do just that, says The Economist. Inflows into “active” ETFs have surged from less than $5 billion in 2019 to over $100 billion last year. Investors should be wary. ETFs have revolutionised markets.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
But active ETFs are undoing that progress, charging high fees in exchange for complicated promises of “volatility protection”, or exposure to illiquid assets in private equity and debt. They are usually a “rip-off”. Another popular trend is “thematic” ETFs, which let investors play everything from pet care to Chinese cloud computing, says James Mackintosh in The Wall Street Journal. But the approach is failing.
Artificial intelligence (AI) has dominated markets for most of this year, yet AI-themed ETFs have actually underperformed the US and global stock benchmarks (you would have done better by just buying Nvidia). Three AI ETFs even managed to shed value in 2024 – picking the right theme at the right time and still losing money must be “galling”.
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
-
Hargreaves Lansdown slashes fees for ISA and SIPP investors - how does it compare to other providers?Hargreaves Lansdown, the UK’s biggest investment platform, has dropped its fees by 40%, to their lowest ever level, for certain customers. Is it a good deal, and how does it compare to other providers?
-
BP's 'long, painful decline' – and why next year could be even tougherOpinion Long-suffering shareholders in oil giant BP have been pushing for change. It won’t come soon enough, says Matthew Lynn
-
BP's 'long, painful decline' – and why next year could be even tougher
Opinion Long-suffering shareholders in oil giant BP have been pushing for change. It won’t come soon enough, says Matthew Lynn
-
Investment trusts tap the profits in exotic and obscure global marketsOpinion Peter Walls, manager of the Unicorn Mastertrust fund, highlights three investment trusts as he shares where he'd put his money
-
Falling revenues and mounting debt spell trouble for Jumia TechnologiesStruggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
-
Best of British bargains: cash in on undervalued companies in the UK stock marketOpinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
-
Building firm Keller presents low debt and ample scope for growthGeotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
-
PZ Cussons share price down 75% in last decade – why it's one to watchOpinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
-
Cash in on the biotech sector with specialist trust BioPharmaOpinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
